Company intelligence / Profile preview
TYK Medicines
Shanghai, Shanghai Municipality, Chinatykmedicines.com ↗
- Ownership
- Private
- Employees
- ~144
- Development stage
- Preclinical
01
Overview
TYK Medicines has a robust pipeline of targeted oncology therapies. Its lead candidate TY‑9591 targets EGFR-mutant NSCLC with brain metastases. Other assets include inhibitors for CDKs and RET-driven cancers. The company leverages proprietary small molecule platforms and PROTAC technology to address unmet needs in oncology. Several programs are in early clinical development.
- Therapeutic areas
- Oncology
- Modalities
- small moleculesPROTACsmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on TYK Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TYK Medicines.